Carl-Johan Dalsgaard Appointed New CEO of Vicore Pharma
The board of directors of Vicore Pharma Holding AB (”Vicore”) has on August 29, 2018 appointed Dr. Carl-Johan Dalsgaard as new CEO of Vicore. Carl-Johan Dalsgaard is CEO of INIM Pharma AB which was recently acquired by Vicore. He is a trained physician and PhD from the Karolinska Institute and has over 25 years of experience from drug development with Astra/AstraZeneca and several biotech companies.
Carl-Johan Dalsgaard replaces Per Jansson who has been the CEO of Vicore Pharma Holding AB since 2013 and also the CEO of Vicore Pharma AB since 2007. The appointment was made in light of Vicore’s expanded efforts in the development of treatments for interstitial lung diseases and the acquisition of INIM Pharma, which was founded by venture capital investor HealthCap. He will assume his position as per September 1, 2018.
The appointment of Carl-Johan Dalsgaard and the acquisition of INIM Pharma means that Vicore forms a more articulated strategy for its future operations, including the implementation of a focused orphan drug culture with focus on interstitial lung diseases and the development of the company’s pipeline to significant value enhancing clinical development stages.
Since 2000, Carl-Johan Dalsgaard has been active as Venture Partner with HealthCap, a leading European life sciences focused venture capital investor. He has started and/or been the CEO of several biotech companies in which HealthCap has invested, including INIM Pharma, Affibody and Biolipox, and in addition, been a board member of additional companies. In connection with the appointment as CEO of Vicore, he will leave his employment with HealthCap.
“When the scope of Vicore’s activities now increases dramatically, and the company’s development programs enter an expanding clinical development phase, the board has decided to hand over to Carl-Johan Dalsgaard and I look forward to the company’s development over the coming years with confidence. Carl-Johan has both a clinical and scientific background as well as extensive experience from drug development, which I am convinced will contribute to the realization of Vicore’s potential. I would like to thank Per Jansson for his valuable contributions which include taking C21 to a clinical development stage, building out the organization, listing the company on NASDAQ First North as well as being key in financing efforts”, says Leif Darner, Chairman of the Board of Directors of Vicore.
“I have been impressed by the data we have seen so far, as well as the biological mechanism of action that C21 addresses, and believe that INIM’s development project for interstitial lung diseases complements C21 in a very good way. With these two unique development programs, I see a real opportunity to create a global leading company focused on severe and rare lung diseases, an area with a large unmet medical need”, says Carl-Johan Dalsgaard.
For further information, please contact:
Leif Darner, Chairman of the Board of Directors: +46-705-79 04 62, firstname.lastname@example.org
This information is information that Vicore Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 08:00 CET on August 30, 2018.
About Vicore Pharma Holding
Vicore Pharma AB is focused on the development of drugs for the treatment of interstitial lung diseases. The company’s two major development programs, VP01 (C21) and VP02 (IMiD), act through the AT2 receptor and is an immunomodulatory drug substance class being developed for local treatment, respectively. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. VP02 has in earlier experiments shown an effect in e.g. idiopathic pulmonary fibrosis with another administration form which, however, has limited its continued development. VP02 is being developed for local treatment in order to e.g. overcome such shortcomings. The company is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com